| Description | TBCA (Casein Kinase II Inhibitor III, TBCA) is a highly selective CK2 (casein kinase II) inhibitor, IC50 = 110 nM, Ki = 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases. |
| In vitro | TBCA inhibits CK2 double mutant (Val66 Ile174) with an IC50 of 0.68 μM. TBCA (0-100 μM; 24 hours) shows a drastic effect on Jurkat cells viability [1]. TBCA dose-dependently inhibits platelet aggregation and secretion induced by various agonists including CRP, 2-MeSADP, AYPGKF and SFLLRN. TBCA also inhibits phosphorylation of PDK1, Akt, and GSK3β induced by AYPGKF[2]. |
| Synonyms | Casein Kinase II Inhibitor III, TBCA |
| molecular weight | 463.74 |
| Molecular formula | C9H4Br4O2 |
| CAS | 934358-00-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (97.04 mM), Sonication is recommended. |
| References | 1. Pagano MA, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8(1):129-139. 2. Ryu SY, Kim S. Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013;720(1-3):391-400. |